26 Nov, 2024 IPOs in Life Sciences By James Baillieu Fiona McFarlane The amount of capital required to develop and bring a drug to market is significant. It is estimated that it costs US$1-2 billion to...
18 Oct, 2024 Venture Capital and Venture Debt in Life Sciences By James Baillieu In recent decades, venture capital (VC) has played an increasingly important role in the high-risk and high-reward life sciences sector....
02 Oct, 2024 Navigating the Complex Landscape of Merger Control and Foreign Direct Investment in Life Sciences in the EU and UK By James Baillieu Dr Saskia King In the rapidly evolving world of life sciences, merger control and foreign direct investment (“FDI”) regimes have emerged as key...